Patient and transplantation characteristics of 84 patients who underwent transplantation between 2003 and 2008
| . | Allo SCT in 1st CP . | Total allo SCT in 1st CP . | Allo SCT in advanced phases . | |
|---|---|---|---|---|
| Early allo SCT . | Imatinib failure in 1st CP . | |||
| No. | 19 | 37 | 56 | 28 |
| Euro score15 (%) | ||||
| High | 6 (32) | 10 (27) | 15 (27) | 9 (32) |
| Intermediate | 3 (15) | 13 (35) | 17 (30) | 8 (29) |
| Low | 10 (53) | 14 (38) | 24 (43) | 11 (39) |
| Sokal score21 (%) | ||||
| High | 6 (32) | 17 (46) | 23 (41) | 11 (39) |
| Intermediate | 2 (10) | 7 (19) | 9 (16) | 7 (25) |
| Low | 11 (58) | 13 (35) | 24 (43) | 10 (36) |
| Sex (% male) | 12 (63) | 21 (57) | 33 (59) | 22 (79) |
| Age at diagnosis, y, median (range) | 35 (16-56) | 38 (21-56) | 37 (16-56) | 38 (18-62) |
| Time to transplantation mo, median (range) | 9.0 (4.8-23.6) | 17.6 (5.0-53.7) | 14.2 (4.8-53.7) | 12.8 (3.5-55.1) |
| EBMT score16 (%) | ||||
| 0-1 | 8 (42) | 4 (11) | 12 (21) | 0 |
| 2 | 3 (16) | 4 (11) | 7 (13) | 1 (4) |
| 3-4 | 8 (42) | 27 (73) | 35 (62) | 9 (32) |
| 5 or higher | 0 | 2 (5) | 2 (4) | 18 (64) |
| Best response before SCT (%) | ||||
| CHR | 18 (95)* | 30 (81) | 48 (86) | 15 (54) |
| Any CyR less than 95% Ph+ metaphases | 11/15 (73) | 27/35 (77) | 38/50 (76) | 10/24 (42) |
| Minor CyR 35%-65% Ph+ metaphases | 3/15 (20) | 2/35 (6) | 5/50 (10) | 2/24 (8) |
| MCyR 1%-34% Ph+ metaphases | 3/15 (20) | 8/35 (23) | 11/50 (22) | 3/24 (13) |
| CCyR 0% Ph+ metaphases | 5/15 (33) | 11/35 (31) | 16/50 (32) | 5/24 (21) |
| MMR | 2/16 (13) | 3/32 (9) | 5/48 (10) | 2/19 (10) |
| Molecular response after SCT (%) | ||||
| CMR | 13/16 (81) | 25/28 (89) | 38/44 (86) | 14/15 (93) |
| Transplant source (%) | ||||
| Sibling | 10 (53) | 11 (30) | 21 (37) | 9 (32) |
| Unrelated | 9 (47) | 26 (70) | 35 (63) | 19 (68) |
| PB | 13 (68) | 28 (76) | 41 (73) | 23 (82) |
| BM | 6 (32) | 9 (24) | 15 (27) | 5 (18) |
| Conditioning therapy (%)† | ||||
| Standard | 15 (79) | 24 (65) | 39 (70) | 18 (64) |
| Reduced | 3 (16) | 5 (13) | 8 (14) | 3 (11) |
| Other/na | 1 (5) | 6/2 (22) | 7/2 (16) | 6/1 (25) |
| GvHD, at any time point (%) | ||||
| All | 11 (58) | 25 (68) | 36 (54) | 20 (71) |
| Grade 3-4 | 4 (20) | 7 (19) | 11 (20) | 10 (35) |
| Chronic | 7 (35) | 13 (36) | 20 (36) | 6 (21) |
| Mortality | ||||
| All | 2 | 2 | 4 | 10 |
| TRM | 2 | 2 | 4 | 5 |
| CML | 0 | 0 | 0 | 4 |
| Unclass | 0 | 0 | 0 | 1 |
| Survival at 3 years after allo SCT, % | 88.2 | 94.1 | 91.4 | 58.8 |
| . | Allo SCT in 1st CP . | Total allo SCT in 1st CP . | Allo SCT in advanced phases . | |
|---|---|---|---|---|
| Early allo SCT . | Imatinib failure in 1st CP . | |||
| No. | 19 | 37 | 56 | 28 |
| Euro score15 (%) | ||||
| High | 6 (32) | 10 (27) | 15 (27) | 9 (32) |
| Intermediate | 3 (15) | 13 (35) | 17 (30) | 8 (29) |
| Low | 10 (53) | 14 (38) | 24 (43) | 11 (39) |
| Sokal score21 (%) | ||||
| High | 6 (32) | 17 (46) | 23 (41) | 11 (39) |
| Intermediate | 2 (10) | 7 (19) | 9 (16) | 7 (25) |
| Low | 11 (58) | 13 (35) | 24 (43) | 10 (36) |
| Sex (% male) | 12 (63) | 21 (57) | 33 (59) | 22 (79) |
| Age at diagnosis, y, median (range) | 35 (16-56) | 38 (21-56) | 37 (16-56) | 38 (18-62) |
| Time to transplantation mo, median (range) | 9.0 (4.8-23.6) | 17.6 (5.0-53.7) | 14.2 (4.8-53.7) | 12.8 (3.5-55.1) |
| EBMT score16 (%) | ||||
| 0-1 | 8 (42) | 4 (11) | 12 (21) | 0 |
| 2 | 3 (16) | 4 (11) | 7 (13) | 1 (4) |
| 3-4 | 8 (42) | 27 (73) | 35 (62) | 9 (32) |
| 5 or higher | 0 | 2 (5) | 2 (4) | 18 (64) |
| Best response before SCT (%) | ||||
| CHR | 18 (95)* | 30 (81) | 48 (86) | 15 (54) |
| Any CyR less than 95% Ph+ metaphases | 11/15 (73) | 27/35 (77) | 38/50 (76) | 10/24 (42) |
| Minor CyR 35%-65% Ph+ metaphases | 3/15 (20) | 2/35 (6) | 5/50 (10) | 2/24 (8) |
| MCyR 1%-34% Ph+ metaphases | 3/15 (20) | 8/35 (23) | 11/50 (22) | 3/24 (13) |
| CCyR 0% Ph+ metaphases | 5/15 (33) | 11/35 (31) | 16/50 (32) | 5/24 (21) |
| MMR | 2/16 (13) | 3/32 (9) | 5/48 (10) | 2/19 (10) |
| Molecular response after SCT (%) | ||||
| CMR | 13/16 (81) | 25/28 (89) | 38/44 (86) | 14/15 (93) |
| Transplant source (%) | ||||
| Sibling | 10 (53) | 11 (30) | 21 (37) | 9 (32) |
| Unrelated | 9 (47) | 26 (70) | 35 (63) | 19 (68) |
| PB | 13 (68) | 28 (76) | 41 (73) | 23 (82) |
| BM | 6 (32) | 9 (24) | 15 (27) | 5 (18) |
| Conditioning therapy (%)† | ||||
| Standard | 15 (79) | 24 (65) | 39 (70) | 18 (64) |
| Reduced | 3 (16) | 5 (13) | 8 (14) | 3 (11) |
| Other/na | 1 (5) | 6/2 (22) | 7/2 (16) | 6/1 (25) |
| GvHD, at any time point (%) | ||||
| All | 11 (58) | 25 (68) | 36 (54) | 20 (71) |
| Grade 3-4 | 4 (20) | 7 (19) | 11 (20) | 10 (35) |
| Chronic | 7 (35) | 13 (36) | 20 (36) | 6 (21) |
| Mortality | ||||
| All | 2 | 2 | 4 | 10 |
| TRM | 2 | 2 | 4 | 5 |
| CML | 0 | 0 | 0 | 4 |
| Unclass | 0 | 0 | 0 | 1 |
| Survival at 3 years after allo SCT, % | 88.2 | 94.1 | 91.4 | 58.8 |
allo SCT indicates allogeneic stem cell transplantation; 1st CP, first chronic phase; EBMT, European Group for Blood and Marrow Transplantation; CHR, complete hematologic remission; CyR, cytogenetic response; Ph+, Philadelphia chromosome positive; MCyR, major cytogenetic remission; CCyR, complete cytogenetic remission; MMR, major molecular remission; CMR, complete molecular remission; PB, peripheral blood; BM, bone marrow; GVHD, graft-versus-host disease; na, not available; TRM, transplantation-related mortality; and unclass, unclassifiable; and CML, chronic myeloid leukemia.
Spleen size not evaluable in 4 cases.
Cyclosporin A ± busulfan ± antithymocyte globulin ± TBI and others.